Previous 10 | Next 10 |
BOSTON and LONDON, June 10, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced t...
Orchard Therapeutics ( ORTX ) has priced its public offering of 9M shares, for total gross proceeds of ~$128M million. More news on: Orchard Therapeutics plc, Healthcare stocks news Read more ...
BOSTON and LONDON, June 05, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced t...
Gainers: Castor Maritime (NASDAQ: CTRM ) +39% . CohBar (NASDAQ: CWBR ) +29% . BIOLASE (NASDAQ: BIOL ) +25% . Regional Health Properties (NYSEMKT: RHE ) +25% . Basic Energy Services (NYSE: BAS ) +24% . Soliton (NASDAQ: SOLY ) +21% . CEL-SCI Corporation (NYSEMKT: CVM ) +21% . Su...
Orchard Therapeutics (NASDAQ: ORTX ) has launched a proposed public offering of 9M American Depositary Shares (“ADSs”) representing 9M ordinary shares. More news on: Orchard Therapeutics plc, Healthcare stocks news, Read more ...
BOSTON and LONDON, June 03, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced t...
Orchard Therapeutics plc (ORTX) Q1 2019 Earnings Conference Call May 28, 2019 8:00 A.M. ET Company Participants Renee Leck - Director, Investor Relations Mark Rothera - President, Chief Executive Officer Bobby Gaspar - Chief Scientific Officer Frank Thomas - Chief Financial Off...
Orchard Therapeutics ( ORTX +0.1% ) has in-licensed an autologous hematopoietic stem cell gene therapy program for the potential treatment of mucopolysaccharidosis type I (MPS-I) developed by Milan, Italy-based San Raffaele-Telethon Institute for Gene Therapy. More news on: Orchard The...
Orchard Therapeutics (NASDAQ: ORTX ): Q1 GAAP EPS of -$0.35 beats by $0.14 . More news on: Orchard Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
New Collaboration with Fondazione Telethon and Ospedale San Raffaele for Clinical Program in Mucopolysaccharidosis Type I (MPS-I) Using Ex Vivo Autologous Hematopoietic Stem Cell Gene Therapy Anticipated Marketing Authorization Application (MAA) Submission for the Treatment of Metachr...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....